scholarly journals The Effects of Low Pressure Domiciliary Non-Invasive Ventilation on Clinical Outcomes in Patients with Severe COPD Regardless Having Hypercapnia

2021 ◽  
Vol Volume 16 ◽  
pp. 817-824
Author(s):  
Christiaan Theunisse ◽  
Huibert H Ponssen ◽  
Netty T C de Graaf ◽  
Maaike Scholten-Bakker ◽  
Sten P Willemsen ◽  
...  

2017 ◽  
Vol 127 ◽  
pp. 69-70
Author(s):  
Yong-er Ou ◽  
Zhi-min Lin ◽  
Wei-liang Wu ◽  
Qun Luo ◽  
Rong-Chang Chen


Author(s):  
Grace Mcdowell ◽  
Hannah Toellner ◽  
Duncan Macfarlane ◽  
Robin Tourish ◽  
Christopher Canavan ◽  
...  


2021 ◽  
Vol 14 (4) ◽  
pp. 176
Author(s):  
Zubia Jamil ◽  
Samreen Khalid ◽  
ShahidMumtaz Abbasi ◽  
Yasir Waheed ◽  
Jamal Ahmed


2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Vaishali Gupte ◽  
Rashmi Hegde ◽  
Sandesh Sawant ◽  
Kabil Kalathingal ◽  
Sonali Jadhav ◽  
...  

Abstract Background Real-world data on safety and clinical outcomes of remdesivir in COVID-19 management is scant. We present findings of data analysis conducted for assessing the safety and clinical outcomes of remdesivir treatment for COVID-19 in India. Methods This retrospective analysis used data from an active surveillance programme database of hospitalised patients with COVID-19 who were receiving remdesivir. Results Of the 2329 patients included, 67.40% were men. Diabetes (29.69%) and hypertension (20.33%) were the most common comorbidities. At remdesivir initiation, 2272 (97.55%) patients were receiving oxygen therapy. Remdesivir was administered for 5 days in 65.38% of patients. Antibiotics (64.90%) and steroids (47.90%) were the most common concomitant medications. Remdesivir was overall well tolerated, and total 119 adverse events were reported; most common were nausea and vomiting in 45.40% and increased liver enzymes in 14.28% patients. 84% of patients were cured/improved, 6.77% died and 9.16% showed no improvement in their clinical status at data collection. Subgroup analyses showed that the mortality rate was significantly lower in patients < 60 years old than in those > 60 years old. Amongst patients on oxygen therapy, the cure/improvement rate was significantly higher in those receiving standard low-flow oxygen than in those receiving mechanical ventilation, non-invasive ventilation, or high-flow oxygen. Factors that were associated with higher mortality were age > 60 years, cardiac disease, diabetes high flow oxygen, non-invasive ventilation and mechanical ventilation. Conclusion Our analysis showed that remdesivir is well tolerated and has an acceptable safety profile. The clinical outcome of cure/improvement was 84%, with a higher improvement in patients < 60 years old and on standard low-flow oxygen.





Medicine ◽  
2021 ◽  
Vol 100 (4) ◽  
pp. e24443
Author(s):  
Mohamad Y. Khatib ◽  
Mohamed Z. Peediyakkal ◽  
Moustafa S. Elshafei ◽  
Hani S. Elzeer ◽  
Dore C. Ananthegowda ◽  
...  








Sign in / Sign up

Export Citation Format

Share Document